Heartscape Technologies, Inc. is a privately held venture funded company engaged in the development and marketing of the PRIME ECG® System (PRIME), a breakthrough medical device that is designed to allow more accurate and rapid diagnosis of heart attacks (acute myocardial infarction or AMI) and ischemia. PRIME is a patented, FDA approved product with an annual US market opportunity of approximately $1 billion.

PRIME has been designed with the ideal mix of sophistication and user-friendliness to encourage widespread adoption in clinical practice. Proprietary software creates a series of intuitive, color displays flagging potential areas of concern. Via a simple touch screen, the physician or caregiver can quickly view the images suggestive of poor blood flow (tissue ischemia, injury or death) or other heart problems. These easily interpreted graphics contrast markedly with the conventional ECG signal display that is often challenging to interpret.

Financials

Date	Type	Amount	Investors	Valuation
04/24/07	Series B	17M	Scottish Equity Partners, Investor Growth Capital	Unknown

People

Competitors